105,95 €
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
53 °P sammeln
105,95 €
105,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
53 °P sammeln
Als Download kaufen
105,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
53 °P sammeln
Jetzt verschenken
105,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
53 °P sammeln
  • Format: ePub

Advances in Cancer Research, Volume 152 , the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.
Provides the latest information on cancer research | Offers outstanding and original reviews on a range of cancer research topics | Serves as an indispensable reference for researchers and students alike

  • Geräte: eReader
  • mit Kopierschutz
  • eBook Hilfe
  • Größe: 33.65MB
Produktbeschreibung
Advances in Cancer Research, Volume 152, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.

  • Provides the latest information on cancer research
  • Offers outstanding and original reviews on a range of cancer research topics
  • Serves as an indispensable reference for researchers and students alike

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.